Biologics Approved In 2011
Year-to-date listing of novel biologic entities approved by FDA.
You may also be interested in...
The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.
Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.
Chad Reynolds of RMQ+ spoke to Medtech Insight about practical strategies for managing economic operators efficiently and with a view to long-term compliance.